


Valens™ T4Q

Novel TLR4 Agonist & QS-21 Adjuvant System






Valens™T4Q: similar system to Liposomal MPLA + Q-21

Valens T4Q is an adjuvant system combining **INI-2002**, a fully synthetic TLR4 agonist with, QS-21 in a liposome formulation.

T4Q is comparable to adjuvant systems already approved for human vaccines, such as vaccines that protect against malaria and herpes zoster (shingles).

In an in vivo murine model, vaccination with Valens T4Q adjuvanted influenza antigen induces a Th1-biased immune response. This adjuvant-induced Th1-biased immune response

is consistent with the performance of an approved adjuvant system containing the immunostimulatory components MPLA and QS-21.



Key Advantages:

- Robust IP Protection and available for licensing
- Outstanding Chemical and Colloidal Stability.
- One version, currently available at cGMP scale.
- Customized options available upon request.

RUO samples, relevant Data and expert Assistance are Available to Support your Development.

www.spipharma.com

salesinfo@spipharma.com

All information and statements given in this bulletin are believed to be accurate at the time of publication. However, neither SPI Pharma nor any of their affiliates make any representations or warranty with respect thereto, including, but not limit to, any results obtained in the processing of the products by customers or any third party. All information and statements are intended for persons having the required skill and know-how and do not relieve the customer or user from verifying the suitability of information and statements given for a specific purpose prior to use of products. It is entirely the obligation of the customer or user to comply with applicable laws and regulations, and with all patent or other intellectual property rights of third parties.